Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020Research in context
Summary: Background: Perceived delays in cancer drug approvals have been a major concern for policymakers in China. Policies have been implemented to accelerate the launch of new cancer drugs and indications. This study aimed to assess similarities and differences between China and the United States...
Saved in:
Main Authors: | Yuxuan Wei (Author), Yichen Zhang (Author), Ziyue Xu (Author), Guoan Wang (Author), Yue Zhou (Author), Huangqianyu Li (Author), Luwen Shi (Author), Huseyin Naci (Author), Anita K. Wagner (Author), Xiaodong Guan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005-2020: an observational studyResearch in context
by: Lan Zhang, et al.
Published: (2024) -
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context
by: Adriana M. Ivama-Brummell, et al.
Published: (2023) -
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
by: Mahnum Shahzad, et al.
Published: (2024) -
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
by: Ebru Demirci, et al.
Published: (2023) -
2020 FDA/EMA approvals for new immunotherapy drug technologies and applications
by: Maryam Monajati, et al.
Published: (2021)